

DATE:	28 November 2022
TO:	All Pathologists and Hematologists/Oncologists
FROM:	Molecular Pathology Program, Alberta Precision Laboratories
RE:	Sendout Testing for MYD88 L265P

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- As of November 28, 2022, all MYD88 L265P test requests received in North and South Sector Molecular Pathology Labs of APL will be sent out to Mayo Clinic Laboratories (Rochester, MN, USA). This change is anticipated to improve sensitivity, reduce turnaround time, and reduce cost. Results will be transcribed and issued by the Molecular Pathology laboratory into the electronic medical record (EMR). This process is current state for the North Sector.

Background

- MYD88 L265P is a diagnostic biomarker for lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia and can aid in distinguishing this from other lymphoma types.
- Testing in Alberta has previously been performed by Myeloid Next Generation Sequencing (NGS) panels. However, genes other than MYD88 are not generally pertinent in this clinicopathologic setting. In addition, neoplastic cell percentage is often low in these cases, which can result in MYD88 L265P below the limit of detection (LOD) of the NGS panels (5% variant allele fraction, VAF), and the potential for a false negative result.
- MYD88 L265P allele-specific PCR performed at Mayo Clinic Laboratories has a limit of detection of 1% VAF. The turnaround time is 5 days, and the assay is less expensive than in-house NGS testing.

How this will impact you

- Sending out MYD88 L265P testing to Mayo Clinic Laboratories is anticipated to improve clinical sensitivity, turnaround time, and cost. This will also align lab practice across the province.

Action Required

- Pathologists:** Continue to order MYD88 L265P in the same way. The cases will be flagged in the molecular pathology laboratory and send out testing will be initiated. Look for the results in your local EMR.
- Oncologists and Hematologists:** Look for MYD88 L265P test results in your local EMR.

Effective **November 28, 2022**

Questions/Concerns

- Erik Nohr, Scientific Lead, Molecular Pathology South erik.nohr@albertaprecisionlabs.ca
- Adrian Box, Medical Lead, Molecular Pathology South Adrian.box@albertaprecisionlabs.ca

Approved by

- Dr. Imran Mirza, Medical/Scientific Director, Molecular Pathology Program
- Mark Douesnard, Operations Director, Molecular Pathology Program